Skip to content
Biodatica
Start free

Regeneron Pharmaceuticals

Gilbert, Arizona

OncologyvaccinePhase IIIListed · REGN

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase III trial registered: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

5d agoTrial registeredJul 13, 2026Source filing (opens the source filing in a new tab)

Momentum

100no change

Momentum 100 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1/PHASE2 registered

    Jul 23, 2026

    Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) · NOT_YET_RECRUITING · sponsor: Regeneron Pharmaceuticals · REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

    ClinicalTrials.gov · NCT07675824 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Jun 11, 2026

    Paroxysmal Nocturnal Hemoglobinuria · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently

    ClinicalTrials.gov · NCT07154745 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    May 7, 2026

    Healthy Volunteer · NOT_YET_RECRUITING · sponsor: Regeneron Pharmaceuticals · A First in Human Study to Assess Safety, Tolerability and Pharmacokinetics of a Single Dose of REGN22044 in Healthy Adults

    ClinicalTrials.gov · NCT07526116 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Jan 2, 2025

    Cutaneous Squamous Cell Carcinoma (CSCC) · RECRUITING · sponsor: Regeneron Pharmaceuticals · Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

    ClinicalTrials.gov · NCT06585410 (opens the source filing in a new tab)

  5. Trial

    PHASE3 registered

    Dec 16, 2024

    Generalized Lipodystrophy · ACTIVE_NOT_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)

    ClinicalTrials.gov · NCT06548100 (opens the source filing in a new tab)

  6. Trial

    PHASE3 registered

    Nov 6, 2024

    Allergic Conjunctivitis · COMPLETED · sponsor: Regeneron Pharmaceuticals · A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy

    ClinicalTrials.gov · NCT06602726 (opens the source filing in a new tab)

  7. Trial

    PHASE3 registered

    Oct 30, 2024

    Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

    ClinicalTrials.gov · NCT06541704 (opens the source filing in a new tab)

  8. Trial

    PHASE2 registered

    Jan 30, 2024

    Smoldering Multiple Myeloma (SMM) · ACTIVE_NOT_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

    ClinicalTrials.gov · NCT05955508 (opens the source filing in a new tab)

  9. Trial

    PHASE3 registered

    Nov 14, 2023

    Follicular Lymphoma (FL) · ACTIVE_NOT_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma

    ClinicalTrials.gov · NCT06097364 (opens the source filing in a new tab)

  10. Trial

    PHASE2 registered

    Apr 21, 2023

    Advanced Non-Small Cell Lung Cancer · ACTIVE_NOT_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

    ClinicalTrials.gov · NCT05557591 (opens the source filing in a new tab)

  11. Trial

    PHASE3 registered

    Mar 7, 2023

    Paroxysmal Nocturnal Hemoglobinuria · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

    ClinicalTrials.gov · NCT05744921 (opens the source filing in a new tab)

  12. Trial

    PHASE1/PHASE2 registered

    Aug 2, 2022

    Chronic Kidney Disease (CKD) · ACTIVE_NOT_RECRUITING · sponsor: Regeneron Pharmaceuticals · A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

    ClinicalTrials.gov · NCT05092347 (opens the source filing in a new tab)

  13. Trial

    PHASE2 registered

    Mar 11, 2021

    Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma · TERMINATED · sponsor: Regeneron Pharmaceuticals · CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma

    ClinicalTrials.gov · NCT04698187 (opens the source filing in a new tab)

  14. Trial

    PHASE1/PHASE2 registered

    Aug 12, 2019

    Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) · RECRUITING · sponsor: Regeneron Pharmaceuticals · A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    ClinicalTrials.gov · NCT03972657 (opens the source filing in a new tab)

  15. Trial

    PHASE1 registered

    Apr 12, 2016

    Melanoma · COMPLETED · sponsor: Regeneron Pharmaceuticals · Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

    ClinicalTrials.gov · NCT02680184 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources